PALB2 and prostate carcinoma: P/LP/D status aggregated across BRCA2, ATM, NBN, and PALB2 was strongly associated with risk of overall prostate cancer (OR = 4.51; 95% CI = 2.18–9.33; P = 4.75 × 10−05) and metastatic disease (OR = 6.92; 95% CI = 2.34–20.49; P = 4.76 × 10−04; Supplementary Table S4), as reported previously (5).